Hikma Pharmaceuticals PLC : Attractive price levels
| Entry price | Target | Stop-loss | Potential |
|---|
|
GBX 1,909.5 |
GBX 2,030 |
GBX 1,840 |
+6.31% |
|---|
After several weeks of decline, shares in Hikma Pharmaceuticals plc are approaching an important technical support area around 1872 GBp on the weekly chart. These levels represent attractive entry points.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● The company has solid fundamentals for a short-term investment strategy.
● The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at GBp 1872 GBp in weekly data.
● The company returns high margins, thereby supporting business profitability.
● The company is in a robust financial situation considering its net cash and margin position.
● For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 1872 GBp
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
HIKMA PHARMACEUTICALS PLC 
